mrtipars: your last rather empty and name calling post does not deserve a response but to put you on "ignore user" bye bye will never read your posts again.
In the meantime it goes down more than 5% on Sunday in Tel-Aviv
I am not a short seller. Would like however to know if what orae_48 wrote is true. Did Edomi sell his shares or not ? perhaps it never happened. do you know ?
Sentiment: Strong Sell
If this is indeed true, is it possible that his last presentation and speech was intended to make us buy the shares he intended to sell ? What does he know that we don't ? I assume many of us lost a lot of money. Or may be this never happened and he did not sell his shares ?.anybody knows for sure ?
Sentiment: Strong Sell
Hallelujah brother ! Chairman Phillip Frost says he will step down at the end of this year.
Perhaps TEVA will start its move upward.
Teva and Celebrex maker Pfizer (PFE) reached a settlement on April 17 regarding Teva's generic version which it plans to launch in December of this year. According to IMS, the branded product generated $2.2B in U.S. sales in 2013.
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party. On September 6, 2012, the three opponents commenced an opposition proceeding against European Patent EP 2 177 528, a patent for COPAXONE® (glatiramer acetate injection) expiring September 9, 2025. In today's hearing, the European Patent Office specifically determined that claims 1-12 of the '528 patent are valid. Therefore infringing follow-on glatiramer products would not be able to launch prior to patent expiry.
can this be charged to Dr. Phillip Frost, former Chairman and CEO of IVAX Corporation ?
I find the following bloomberg article encouraging and promising as to the future of TEVA
I tend to agree with redshington_washskins2 and his comment about Yanai's possible motives
In 2009 TEVA's CEO Shlomo Yanai reduced the investment in R&D from about 19% to about 6% of sales
This number did not change significantly since then and it is about 7 % of sales now.
Is this information correct ? (the source of the graph mentioned below is from Morningstar)
Does anybody know what was Yanai's rational in making this cut which has an important impact on TEVA's future ?
Did Levine intend to change this number before he left ?
See the graph in
MNTA presented its plans at the Credit Suisse Healthcare Conference and I find it very informative. It seems that 2014 will be an important year in MNTA's work and drugs development. In particular
if MNTA will be successful in creating a higher standard of structural characterization and fingerprint like similarity between MNTA's product and the branded products, there is a strong possibility that there may be reduced clinical requirement associated with MNTA's products
Rather good news for TEVA's future
and any comments about this:
Eli Lilly's Cymbalta goes generic in December. Sales of Cymbalta by Lilly are expected to fall from about $5B to $1.5B about 70% drop in sales. MNTA is going to catch a piece of the action (unfortunately, others too, including TEVA) . This seem to predict a bleak outlook for Lilly and an important addition to the bright future of MNTA.